Ion Genomics Podcast
Claim This Podcastby Andrew P. Han
Podcast Overview
<p>Ion Genomics brings you in-depth but also wide-ranging conversations with leading figures in genomic science and technology. </p><p></p><p>Hosted by veteran science journalist Andrew P. Han, the Ion Genomics Podcast is a weekly window into the latest advances driving exploration of human biology. </p><p></p><p>For more science and business news, check out <a rel="noopener noreferrer nofollow" href="http://www.iongenomics.bio" target="_blank">www.iongenomics.bio</a> and subscribe to the newsletter.</p>
Language
🇺🇲
Publishing Since
4/24/2026
1 verified contact email on file for Ion Genomics Podcast
Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.
Recent Episodes
June 26, 2026
Maximal Cancer Diagnostics with Sid Sijbrandij and Jacob Stern
<p>In 2024, Sid Sijbrandij got the news that no cancer patient wants to hear: his tumor was back and his doctors told him they had nothing left to offer. </p><p></p><p>Sid, a tech entrepreneur who up until that point had been running his company, GitLab, went all in, doing as much testing and as many treatments as he could. </p><p></p><p>It seems to have worked. Moreover, Sid’s team thinks they’ve been able to figure out what went right, thanks to heaps of molecular data they’ve collected, including single-cell sequencing data.</p><p></p><p>“It's very difficult, if not impossible, to do causative work in an N-of-1 study, but because we have this longitudinal sampling over the course of Sid's case, we can start to build a mechanistic hypothesis,” said Jacob Stern, a single-cell data expert on Sid's team and veteran of 10x Genomics. “Which seems to be that there was a bunch of combination immunotherapy that helped to rev up the immune system over the course of 2024.”</p><p></p><p>Join Sid, Jacob, and I as we discuss the "maximal diagnostics” approach and how Sid plans to bring it to other patients who find themselves in a similar situation.During our chat, Sid mentions that he got a treatment from a company started by a friend he made at the Y Combinator startup accelerator. That company is <a rel="noopener noreferrer nofollow" href="https://www.shasqi.com/leadership" target="_blank">Shasqi</a>, founded by José Oneto.</p><p></p><p>To see a timeline of Sid’s experience and all the data he and his team collected diagnosing and treating his disease check out <a rel="noopener noreferrer nofollow" href="http://osteosarc.com" target="_blank">osteosarc.com</a>.</p><p></p><p>Sid has also written about his experience on his personal <a rel="noopener noreferrer nofollow" href="https://sijbrandij.substack.com/p/im-going-founder-mode-on-my-cancer" target="_blank">Substack.</a></p><p></p><p>For more information about Sid’s policy proposals, check out slide 17 of his embedded PowerPoint at <a rel="noopener noreferrer nofollow" href="https://sytse.com/cancer/" target="_blank">https://sytse.com/cancer/</a></p><p></p><p>For more information about the cancer “playbooks” offered by the Sijbrandij Foundation’s Future of Cancer Care Today program, see:</p><p><a rel="noopener noreferrer nofollow" href="https://sijbrandijfoundation.org/fcct" target="_blank">https://sijbrandijfoundation.org/fcct</a></p><p>More information about the companies Sid is investing in to bring aspects of his maximal diagnostics approach to market is at <a rel="noopener noreferrer nofollow" href="http://Evenone.ventures" target="_blank">Evenone.ventures</a>.</p>
June 19, 2026
Protein Sequencing-by-Subtraction with Pumpkinseed Cofounder/CEO Jen Dionne
<p>“We right now are developing our technology to be able very soon to sequence roughly hundred-length proteins that are on each of those sensors within a 24-hour period. You can think about this as being essentially 10 billion letters per day: 100 million sensors times those 100-mers on each sensor and then sequencing letter by letter.”</p><p></p><p>That’s the scale that Pumpkinseed CEO and Cofounder Jen Dionne thinks her company can reach for analyzing proteins. The technology, developed in her lab at Stanford University, uses Raman spectroscopy to fingerprint molecules and Edman degradation to achieve sequencing-by-subtraction of peptides: 30 amino acids at a time now, possibly up to 300, or full-length proteins, in the future. </p><p></p><p>The ability to capture 10 billion amino acids per day would represent several orders of magnitude better throughput than the best and fastest proteomics methods available today, whether via mass spectroscopy or other single-molecule technologies being developed by competitors like Quantum-Si or Nautilus. </p><p></p><p>Remarkably, that’s still a long way from achieving the data acquisition rate that state-of-the-art high-throughput sequencers can achieve, but it’s enough to start thinking about making the type of impact that the first next-generation sequencers had on biological research. </p><p></p><p>Join us as we discuss the underlying physics behind Pumpkinseed’s technology, Jen’s journey from lab to C-suite, the applications they’re already pursuing, and her love of sports, including the World Cup. </p><p></p><p>For more information, check out <a rel="noopener noreferrer nofollow" href="http://pumpkinseed.bio" target="_blank">pumpkinseed.bio</a> or email Jen. </p><p></p><p>Links to papers discussed in the episode:</p><p>Hu et al. <a rel="noopener noreferrer nofollow" href="https://www.nature.com/articles/s41467-023-39721-w" target="_blank">Rapid genetic screening with high quality factor metasurfaces</a>. <i>Nature Communications</i>, July 26, 2023.</p><p><br />Zhang et al. <a rel="noopener noreferrer nofollow" href="https://pubs.acs.org/doi/abs/10.1021/acsnano.4c04282" target="_blank">From Genotype to Phenotype: Raman Spectroscopy and Machine Learning for Label-Free Single-Cell Analysis</a>. ACS Nano, July 1, 2024.</p><p></p><p>Stiber, et al. <a rel="noopener noreferrer nofollow" href="https://www.biorxiv.org/content/10.64898/2026.02.22.707331v1" target="_blank">Dynamic, single-cell monitoring of CAR T cell identity and activation with Raman spectroscopy</a>. <i>BioRxiv</i>, February 23, 2026.</p>
June 12, 2026
Q1 Company News Roundup with Wall Street Analyst Kyle Mikson
<p>What kind of market share can Illumina expect when it launches its own MRD kits and is it worth the risk of annoying customers that also offer those tests? </p><p>Why did liquid biopsy company stocks do so well in May?</p><p>What were his headline takeaways from the recent American Society of Clinical Oncology annual meeting?</p><p>Where is he going on summer vacation after a hectic several months?</p><p>Tune in to hear the answers to these questions, and more.</p><p></p><p>If you’re interested in learning more about Kyle’s takes on the life science tools and diagnostics industries, you can reach out to him on LinkedIn to start a conversation. </p><p></p><p><a rel="noopener noreferrer nofollow" href="https://www.linkedin.com/in/kylemiksoncfa/" target="_blank">https://www.linkedin.com/in/kylemiksoncfa/</a></p><p></p><p>For full disclosure, he asked me to note that Seer is an investment banking client of Canaccord Genuity.</p>
7 total episodes available
Deep-dive analytics for Ion Genomics Podcast
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is Ion Genomics Podcast?
<p>Ion Genomics brings you in-depth but also wide-ranging conversations with leading figures in genomic science and technology. </p><p></p><p>Hosted by veteran science journalist Andrew P. Han, the Ion Genomics Podcast is a weekly window into the latest advances driving exploration of human biology. </p><p></p><p>For more science and business news, check out <a rel="noopener noreferrer nofollow" href="http://www.iongenomics.bio" target="_blank">www.iongenomics.bio</a> and subscribe to the newsletter.</p> - How often does this podcast release new episodes?
This podcast updates daily.
- Where can I listen to this podcast?
This podcast is available on 4 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
Information about guest appearances is not available.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.